Already have an account? Identify
Fujifilm Holdings Corporation (OTC: FUJIF) has been awarded a $265 million federal contract to support the manufacturing of novel coronavirus (COVID-19) vaccine candidate, the United States Department of Health and Human Services announced Monday.
The unit of the Japanese company Fujifilm Diosynth Biotechnologies outsources production to the Texas A-M Center for Innovation in Advanced Development and Manufacturing (CIADM), a public-private partnership between the Biomedical Advanced Research and Development Authority (BARDA) and Texas A-M University.
The U.S. government She has reserved CIADM’s ability until December 2021 for the progression of COVID-19 vaccines, as a candidate for Novavax, Inc. (NASDAQ: NVAX), as a component of Operation Warp Speed, which she described through HHS Secretary Alex Azar. “one of the greatest vaccine production efforts in recent history.”
Fujifilm announced this week that it had reached an agreement with Novavax to “manufacture a bulk drug” for the Maryland-based coronavirus vaccine candidate at its Morrisville, North Carolina site. Tokyo-based said that “the north carolina to Texas generation movement will begin in late 2020 with increased mass production of the candidate vaccine in early 2021.”
Novavax earned $1.6 billion in federal investment for the NVX-CoV2373 candidate vaccine.
Manufacturing and distribution of a potential vaccine is a key obstacle with manufacturers preparing to overcome such challenges even before a safe vaccine is found to be able to faster deliver the successful candidate, CNBC noted earlier.
On Sunday, Moderna Inc (NASDAQ: MRNA) said it earned another $472 million from the Trump administration, in addition to the original $483 million that had been allocated to its vaccine candidate.
The company also began complex testing of its coronavirus vaccine on Monday, along with another candidate developed through Pfizer Inc (NYSE: PFE) and its German spouse BioNTech SE (NASDAQ: BNTX). Johnson and Johnson (NYSE: JNJ) plans to start complex clinical trials of its candidate vaccine until the scheduled September date.
Fujifilm Holdings OTC shares closed with a rise of $7.02 to $47.09 on Monday.
Thank you for subscribing! If you have any questions, please call us at 1-877-440-ZING or email us at [email protected]